Developing Impactful Therapies
The Therapeutics Discovery team is leveraging its unique bench at the bedside approach to create the next generation of cancer medicines and improve the lives of our patients.
Driven by unmet patient needs, we work to advance new therapies, across all modalities, from the earliest phases of discovery into clinical development, all under one roof. A snapshot of our pipeline is included here, with additional assets being developed by our teams.
We work closely with leading clinical experts at MD Anderson to bring our most promising therapies into clinical studies. Our collaborations with leading biopharmaceutical companies and strategic investors enable us to bring these innovative medicines to our patients quickly, safely and effectively.
Therapeutics Discovery Pipeline
-
IACS-6274
Small-molecule metabolism inhibitor targeting glutaminase in Phase I clinical trials for patients with solid tumors
-
BBP-398
Small-molecule inhibitor of SHP2 oncogene developed for patients with genetically driven and treatment-resistant cancers
-
ION537
First-in-class antisense oligonucleotide targeting transcription factor activated in liver, head and neck cancers
-
ART0380
Small-molecule inhibitor of DNA-damage regulator ATR to be evaluated in patients with a variety of cancer types
-
MAG-8287
Neuroprotective therapy designed for patients with chemotherapy-induced peripheral neuropathy and Alzheimer’s disease
-
IACS-53152
Small-molecule metabolism inhibitor targeting glutaminase in Phase I clinical trials for patients with solid tumors
-
IACS-16559
Small-molecule targeting epigenetic regulator CBP/p300 in development for genetically defined leukemia and lymphoma
-
8F4
First-in-class TCR-like antibody targeting PR1 on leukemia cells in Phase I clinical trials for patients with MDS & AML
-
TSLPR x CD3
Immune-stimulating bispecific antibody targeting TSLPR and CD3 to redirect T cells for the treatment of B-ALL